Inclusion Criteria:  --Participant must be adults.  Participants who have been enrolled in, and has completed Part B of CARDINAL or CADENZA study Participants who have ongoing diagnosis of CAD Participants who continue to require treatment for CAD upon completion of participation in the previous study evidenced by return of CAD-related symptoms of anemia and/or deterioration on markers of hemolysis after the end of study visit following the 9-week safety follow up period. (9-week follow up period). Participants who have acceptable benefit/risk profile Participant who has acceptable infection risk Participants who have no available appropriate alternative therapy for CAD Body weight of ≥39 kg Giving signed informed consent - - - -  Exclusion Criteria:  --Clinical diagnosis of systemic SLE or immune complex mediated autoimmune disorders  Participants who meet recent Rituximab and/or immunosuppressive therapy  Any of the following medical conditions:  Active, serious intercurrent illness which will preclude enrolment until recovery is complete. Pregnancy or breast-feeding End of Study visit in CARDINAL or CADENZA took place more than 3 months before baseline visit in this study. Hypersensitivity reactions to sutimlimab or components thereof, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study